Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Surface Marker

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Cell Surface Marker. Displaying page 1 of 1.
    EudraCT Number: 2006-000985-34 Sponsor Protocol Number: 001:CD40L Start Date*: 2006-06-15
    Sponsor Name:Clinical Immunology Division
    Full Title: A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma
    Medical condition: Urinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017525-19 Sponsor Protocol Number: 77777 Start Date*: 2010-03-12
    Sponsor Name:St. Vincents University Hospital, Department of Rheumatology.
    Full Title: Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients.
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003202-16 Sponsor Protocol Number: PB/0046 Start Date*: 2015-10-20
    Sponsor Name:Academic Medical Centre
    Full Title: A randomized, double-blind, placebo-controlled study to compare the safety and immune effects of multiple doses of vitamin D3 in patients with allergic rhinitis/rhino-conjunctivitis caused by birc...
    Medical condition: subcutaneous immunotherapy in allergic rhinits (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014593-18 Sponsor Protocol Number: CT-2008-01 Start Date*: 2009-12-07
    Sponsor Name:CureTech
    Full Title: CT-2008-01: Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + CT-011 versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously ...
    Medical condition: This study will enroll patients with untreated, metastatic colorectal carcinoma who are eligible for first line FOLFOX therapy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018331-18 Sponsor Protocol Number: ML25243 Start Date*: 2010-05-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMA...
    Medical condition: Adult Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003930-17 Sponsor Protocol Number: 1407-GUCG Start Date*: 2015-10-05
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO...
    Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10043338 Testicular malignant germ cell tumor NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) SI (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001789-13 Sponsor Protocol Number: 2016/02 Start Date*: 2020-01-13
    Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford
    Full Title: A randomised, open label study, exploring the differences in immunogenicity and reactogenicity of infants after immunisation with either an acellular (aP) or whole cell pertussis (wP) vaccine
    Medical condition: This study is going to focus on the immunisations against pertussis disease in previous healthy children, but the disease itself is not going to be study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10034738 Pertussis PT
    21.1 10021881 - Infections and infestations 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005220-26 Sponsor Protocol Number: ACE-LY-308 Start Date*: 2017-05-16
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Un...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005178-43 Sponsor Protocol Number: OMB115991 Start Date*: 2012-02-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
    Medical condition: Untreated or Relapsed Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008968 Chronic lymphocytic leukaemia stage A(0) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004050-16 Sponsor Protocol Number: HEAT-AML Start Date*: 2019-08-01
    Sponsor Name:University Hospital Karolinska
    Full Title: HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard a...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001984-35 Sponsor Protocol Number: M16OPN Start Date*: 2017-06-22
    Sponsor Name:Antoni van leeuwenhoek ziekenhuis
    Full Title: Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
    Medical condition: Patients with stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002125-19 Sponsor Protocol Number: 9494 Start Date*: 2016-06-20
    Sponsor Name:CHU MontpellierCentre administratif André Benech,
    Full Title: A phase IIb, prospective, multicentre, double-blind, triple-arm, randomized versus placebo trial, to assess the efficacy of a single injection of either 2 or 10 x 106 autologous adipose derived mes...
    Medical condition: Active knee Osteoarthritis (mild to moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 08 22:42:25 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA